Damien Ambrosetti
Overview
Explore the profile of Damien Ambrosetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
1434
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Margue G, Klein C, Parier B, Albiges L, Pignot G, Gravis G, et al.
Urol Oncol
. 2024 Nov;
PMID: 39603878
Background: Complete responses to immunotherapy in metastatic kidney cancer have led to a renewed interest in primary-site surgery. The prolonged survival of these patients has prompted consideration for nephron-sparing surgery...
2.
Perrin C, Coutts M, Boukari F, Ambrosetti D
Am J Dermatopathol
. 2024 Mar;
46(5):259-270.
PMID: 38513115
Onychocytic matricoma (OCM) is a benign neoplasm of the nail matrix. Only 18 cases of this tumor have been reported in the literature to date. We retrospectively analyzed the clinical...
3.
Montemagno C, Jacquel A, Pandiani C, Rastoin O, Dawaliby R, Schmitt T, et al.
J Exp Clin Cancer Res
. 2024 Mar;
43(1):86.
PMID: 38504270
Background: In clear cell renal cell carcinoma (ccRCC), first-line treatment combines nivolumab (anti-PD-1) and ipilimumab (anti-CTLA4), yielding long-term remissions but with only a 40% success rate. Our study explored the...
4.
Ponzio F, Descombes X, Ambrosetti D
Sci Rep
. 2023 Sep;
13(1):15887.
PMID: 37741835
The prognosis of renal cell carcinoma (RCC) malignant neoplasms deeply relies on an accurate determination of the histological subtype, which currently involves the light microscopy visual analysis of histological slides,...
5.
Montemagno C, Durivault J, Gastaldi C, Dufies M, Vial V, He X, et al.
Mol Oncol
. 2023 Feb;
17(7):1379-1401.
PMID: 36810959
The efficacy of anti-angiogenic treatment by targeting VEGF/VEGF receptors in metastatic clear cell renal cell carcinoma (ccRCC) varies from patient to patient. Discovering the reasons behind this variability could lead...
6.
Boulenger de Hauteclocque A, Ferrer L, Ambrosetti D, Ricard S, Bigot P, Bensalah K, et al.
BJU Int
. 2023 Jan;
132(2):160-169.
PMID: 36648124
Objectives: To assess the impact of pathological upstaging from clinically localized to locally advanced pT3a on survival in patients with renal cell carcinoma (RCC), as well as the oncological safety...
7.
Perrin C, Pedeutour F, Coutts M, Ambrosetti D, Dadone-Montaudie B
Histopathology
. 2023 Jan;
82(5):767-778.
PMID: 36647795
Aims: Onychomatricoma (OM), an uncommon benign fibroepithelial neoplasm of the nail unit, is sometimes diagnostically challenging for clinicians and pathologists. OM consistently expresses CD34, but no specific immunohistohemical markers or...
8.
Branger N, Bigot P, Pignot G, Lorusso V, Audenet F, Parier B, et al.
World J Urol
. 2023 Jan;
41(2):483-489.
PMID: 36633650
Purpose: To describe clinical features of patients with oncocytoma on renal biopsy (RMB), correlation with final histology on surgically treated patients, and predictive factors of discrepancy between RMB and final...
9.
Morrone A, Bentellis I, Bernhard J, Bensalah K, Champy C, Bruyere F, et al.
Sci Rep
. 2022 Nov;
12(1):18342.
PMID: 36316438
The oncological impact of positive surgical margins (PSM) after robot-assisted partial nephrectomy (RAPN) is still under debate. We compared PSM and Negative Surgical Margins (NSM) in terms of recurrence-free survival...
10.
Hagege A, Saada-Bouzid E, Ambrosetti D, Rastoin O, Boyer J, He X, et al.
Cell Rep Med
. 2022 Sep;
3(9):100659.
PMID: 36130479
Local or metastatic relapse following surgery, radiotherapy, and cisplatin is the leading cause of death in patients with head and neck squamous cell carcinoma (HNSCC). Our study shows overexpression of...